|
Study of Aritinercept in Patients With Generalized Myasthenia Gravis
RECRUITINGPhase 1/2Sponsored by Aurinia Pharmaceuticals Inc.
Actively Recruiting
PhasePhase 1/2
SponsorAurinia Pharmaceuticals Inc.
Started2026-04-22
Est. completion2029-03-02
Eligibility
Age18 Years – 85 Years
Healthy vol.Accepted
Locations3 sites
View on ClinicalTrials.gov →
NCT07596901
Summary
This clinical study will enroll patients with generalized myasthenia gravis (gMG). The goal of this clinical study is to assess the safety, tolerability, effectiveness, pharmacokinetics (how the body processes the drug) and pharmacodynamics (how the drug affects the body) of aritinercept.
Eligibility
Age: 18 Years – 85 YearsHealthy volunteers accepted
Key Inclusion Criteria: * Adult patients (18-85 years old) * Myasthenia Gravis Foundation of America (MGFA) Class II-IV gMG * Additional inclusion criteria are defined in the protocol Key Exclusion Criteria: * Current or medical history of malignancy within the last 5 years * Pregnant, breastfeeding or intending to become pregnant during the Study * Additional exclusion criteria are defined in the protocol
Conditions2
CancerMyasthenia Gravis, Generalized
Interventions1
Locations3 sites
Aurinia Investigational Site
Aurinia Investigational Site
Aurinia Investigational Site
Find trials near these locations
Browse More Trials
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.
Actively Recruiting
PhasePhase 1/2
SponsorAurinia Pharmaceuticals Inc.
Started2026-04-22
Est. completion2029-03-02
Eligibility
Age18 Years – 85 Years
Healthy vol.Accepted
Locations3 sites
View on ClinicalTrials.gov →
NCT07596901